Home > Boards > US Listed > Biotechs >

Aurinia Pharmaceuticals Inc (AUPH)

Add AUPH Price Alert      Hide Sticky   Hide Intro
Moderator: Jesspro
Search This Board: 
Last Post: 2/25/2021 12:24:12 PM - Followers: 209 - Board type: Free - Posts Today: 2

Aurinia is a late-stage biopharmaceutical company providing novel products specifically engineered to treat a limited, targeted patient population suffering from serious disease states for which there is a high unmet medical need.

*Aurinia Pharmaceuticals Inc.





Candidate & Indication Development Stage
Preclinical Phase 1 Phase 2 Phase 3 Market
VOCLOSPORINLupus Nephritis (LN)
Preclinical Phase complete
Phase 1 Phase complete
Phase 2 Phase in progress
Phase 3 Phase not started
Market Phase not started

Aurinia is committed to working in areas of high unmet medical need and is poised to deliver the first approved therapy in the U.S. and Europe for the treatment of lupus nephritis, or LN.

The Voclosporin Advantage

Voclosporin, an investigational drug, is a novel and potentially best-in-class calcineurin inhibitor (“CNI”) with clinical data in over 2,000 patients across indications. Voclosporin is an immunosuppressant, with a synergistic and dual mechanism of action that has the potential to improve near- and long-term outcomes in lupus nephritis (LN) when added to standard of care mycophenolate mofetil (MMF). It has been granted “fast track status” by the U.S. Food & Drug Administration (FDA).

Voclosporin Could Transform the LN treatment Landscape

Voclosporin has the potential to become a best in class medication and the first approved treatment for LN in the U.S. and Europe, effectively altering the current treatment paradigm for the disease.

Advantages of Voclosporin Combined with Standard of Care (SoC)

Our clinical data suggests that adding voclosporin to the current SoC of MMF for the treatment of lupus nephritis (LN) will yield superior results to using the standard of care alone.

Additionally, voclosporin may prove to be an ideal therapy for lupus nephritis due to advantages such as:

  • Improved efficacy
    Increased safety
    Oral administration
    Improved average time to renal response or remission
    Improved duration of renal response
    Reduction in steroid burden
    Potential first line add-on to MMF
    Fewer toxic immunosuppressants required
Benefits of Voclosporin

Potential Benefits of Voclosporin

In clinical trials, Voclosporin has been shown to be especially effective in the presence of low dose steroids with rapid reduction of LN inflammatory markers and overall improved renal stability.

The list of potential product benefits includes:

LN Critical Need Voclosporin (based on AURA Results)
Control of Active Disease
Rapid Disease Control
Lower Steroid Burden
Impact on Extra-renal disease
Convenient Treatment Regimen

In previous studies, over 2000 patients have been treated with Voclosporin with no abnormal or unexpected SAE’s

Well Characterized Safety Profile

Efficacy of calcineurin inhibition has already been established. Voclosporin has a well-characterized safety profile (over 2,000 patient exposures across multiple years) across indications.

No new safety signals were observed with the use of Voclosporin in LN patients; Voclosporin was well-tolerated and renal function remained stable in clinical studies. The overall safety profile is consistent with other immunosuppressive drugs.


Current Price
Bid Ask Day's Range
  • 1D
  • 1M
  • 2M
  • 3M
  • 6M
  • 1Y
  • 2Y
  • 3Y
  • 5Y
News News Alert: Securities Registration: Employee Benefit Plan (s-8) 02/24/2021 04:30:29 PM
#12367   Not junk just a big disappointment LivingTheDream 02/25/21 12:24:12 PM
#12366   Junk biotech_researcher 02/25/21 11:58:02 AM
#12365   ....this is great news until the real revenue Ganz 02/24/21 04:53:26 PM
#12364   probably no one ??? Bullish but ..... yankees7 02/24/21 02:53:59 PM
#12363   I don’t know, but someone has dumped a biotech_researcher 02/24/21 01:31:31 PM
#12362   Earnings today, who’s loading up at this ridiculously Ganz 02/24/21 01:27:52 PM
#12361   https://finance.yahoo.com/news/earnings-preview-aurinia-pharmaceuticals-15294709 thesaud 02/24/21 07:52:25 AM
#12360   the nasdaq is down6% in 2 days correction thesaud 02/23/21 12:16:13 PM
#12359   No, but Aurinia has affectionately entered the dollar biotech_researcher 02/23/21 11:41:22 AM
#12358   are we winning yet? BR are you beginning cervelo 02/23/21 09:53:29 AM
#12357   Good points Jess Ganz 02/22/21 04:04:30 PM
#12356   I expect it is something more than being biotech_researcher 02/22/21 03:49:20 PM
#12355   BR it is monday and it is running, cervelo 02/22/21 11:48:32 AM
#12354   I expect you mean coal?? biotech_researcher 02/22/21 09:53:10 AM
#12353   Aurina being Aurina. At this point in the biotech_researcher 02/22/21 09:52:25 AM
#12352   Jess, Thanks for the explanation. Love your forecast! moosedogger 02/22/21 08:58:58 AM
#12351   Moose, I would think the cytokine storm unleashed Jesspro 02/21/21 09:12:37 AM
#12350   This is kind of interesting (not sure what moosedogger 02/21/21 06:48:31 AM
#12349   Dang. I was hoping to see Denner nsomniyak 02/20/21 10:36:12 AM
#12348   Lupky in the sky with diamonds is Jesspro 02/19/21 07:20:27 PM
#12347   Where the CEO of Ariad (Paris) landed: Blackstone Life biotech_researcher 02/19/21 06:32:22 PM
#12346   Very positive post from our long time friend: moosedogger 02/19/21 01:51:16 PM
#12345   I agree 100% andypro 02/18/21 07:28:33 PM
#12344   Thanks for sharing Moos, back to sleep zzzzzzz. Jesspro 02/18/21 07:21:55 PM
#12343   Moose, you’re en fuego, good job buddy ! Ganz 02/18/21 02:48:09 PM
#12342   from seeking alpha thesaud 02/18/21 02:47:30 PM
#12341   It's not unusual for the price of a Zeppo 02/18/21 12:05:31 PM
#12340   Catalent Announces Commercial Supply Agreement with Aurinia Pharmaceuticals moosedogger 02/18/21 10:51:03 AM
#12339   Correct. All the calls bought need to be unwound. biotech_researcher 02/18/21 10:11:02 AM
#12338   Why do you think February expiration is important? nsomniyak 02/18/21 09:09:39 AM
#12337   Once we pass option expiry this Friday this biotech_researcher 02/18/21 08:52:15 AM
#12336   Interesting timing- the day after ER: Aurinia Pharmaceuticals moosedogger 02/18/21 07:11:41 AM
#12335   Everything looks great except for the market cap. moosedogger 02/17/21 08:20:41 PM
#12334   Zeppo, GSK would be perfect! moosedogger 02/17/21 08:10:57 PM
#12333   Great post moose, Ganz 02/17/21 05:26:41 PM
#12332   GSK also has this information, and, IMHO, would Zeppo 02/17/21 04:21:34 PM
#12331   $12.10 should hold. Diamond hands-hold her there boys...... biotech_researcher 02/17/21 12:18:41 PM
#12330   https://ih.advfn.com/p.php?pid=nmona&article=84357944 thesaud 02/17/21 07:21:44 AM
#12329   Yes sir. Kind of like watching paint dry GIDDY YUP! GLTA Nelson2 02/17/21 05:32:30 AM
#12328   Rheumatologists & Nephrologists call continued......... moosedogger 02/16/21 07:57:24 PM
#12327   Pretty awesome call to Nephrologists and Rheumatologists today: moosedogger 02/16/21 07:35:29 PM
#12326   Let’s get a 3X valuation ok? The deal includes biotech_researcher 02/16/21 04:24:50 PM
#12325   Wake me up too, Thes. Jesspro 02/16/21 03:11:06 PM
#12323   Ganz is dyslexic.. biotech_researcher 02/16/21 12:41:01 PM
#12322   BR is Dennis? How do you figure? moosedogger 02/16/21 12:16:43 PM
#12321   BT, this is the only solid post Ganz 02/16/21 11:33:27 AM
#12320   wake me up when we are sold, man thesaud 02/16/21 10:24:00 AM
#12319   Let’s see if they can bury this today. biotech_researcher 02/16/21 09:36:58 AM
#12318   Good post from Dennis over on Yahoo: No announcement biotech_researcher 02/16/21 08:31:06 AM
#12317   Canadian biotech to prioritize Rockville growth, ‘shift gears’ moosedogger 02/16/21 07:41:39 AM
Consent Preferences